Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Steady progress against HER2-positive breast cancer.

Hayes DF.

N Engl J Med. 2011 Oct 6;365(14):1336-8. doi: 10.1056/NEJMe1101326. No abstract available.

PMID:
21991956
2.

From the molecule to the clinic--inhibiting HER2 to treat breast cancer.

Eisenhauer EA.

N Engl J Med. 2001 Mar 15;344(11):841-2. No abstract available.

PMID:
11248162
3.

HER2 and response to paclitaxel in node-positive breast cancer.

Roukos DH.

N Engl J Med. 2008 Jan 10;358(2):197; author reply 198. No abstract available.

PMID:
18193530
4.

HER2 and response to paclitaxel in node-positive breast cancer.

Ferretti G, Felici A, Cognetti F.

N Engl J Med. 2008 Jan 10;358(2):197; author reply 198. doi: 10.1056/NEJMc073152. No abstract available.

5.

HER2 and response to paclitaxel in node-positive breast cancer.

Nash I.

N Engl J Med. 2008 Jan 10;358(2):198; author reply 198-9. No abstract available.

PMID:
18193532
6.

Trastuzumab combined with paclitaxel after doxorubicin and cyclophosphamide for operable HER2-positive breast cancer.

Ferretti G, Felici A, Papaldo P, Carlini P, Fabi A, Cognetti F.

Oncologist. 2006 May;11(5):533; author reply 534. No abstract available.

7.

Adjuvant trastuzumab in HER2-positive breast cancer.

Vanderhaegen J, Paridaens R, Neven P.

N Engl J Med. 2012 Feb 16;366(7):664; author reply 664-6. doi: 10.1056/NEJMc1112823#SA4. No abstract available.

PMID:
22335750
8.

Adjuvant trastuzumab in HER2-positive breast cancer.

Collins I, Francis P, Mileshkin L.

N Engl J Med. 2012 Feb 16;366(7):664; author reply 664-6. doi: 10.1056/NEJMc1112823#SA3. No abstract available.

PMID:
22335749
9.

Adjuvant trastuzumab in HER2-positive breast cancer.

Mortimer J.

N Engl J Med. 2012 Feb 16;366(7):663-4; author reply 664-6. doi: 10.1056/NEJMc1112823#SA2. No abstract available.

PMID:
22335748
10.

Adjuvant trastuzumab in HER2-positive breast cancer.

Kaji D, Miura Y, Takano T.

N Engl J Med. 2012 Feb 16;366(7):663; author reply 664-6. doi: 10.1056/NEJMc1112823#SA1. No abstract available.

PMID:
22335747
11.

[Breast cancer].

Tokuda Y, Saito Y, Suzuki Y, Ohta M, Tajima T.

Nihon Rinsho. 2002 Mar;60(3):563-9. Review. Japanese.

PMID:
11904974
12.

Refining therapy for human epidermal growth factor receptor 2-positive breast cancer: T stands for trastuzumab, tumor size, and treatment strategy.

Burstein HJ, Winer EP.

J Clin Oncol. 2009 Dec 1;27(34):5671-3. doi: 10.1200/JCO.2009.24.2222. Epub 2009 Nov 2. No abstract available.

PMID:
19884535
13.

New molecule-targeting therapy with herceptin (trastuzumab), an anti-HER2 (c-erB-2) monoclonal antibody.

Sakamoto G, Mitsuyama S.

Breast Cancer. 2000;7(4):350-7. No abstract available.

PMID:
11114864
14.

Trastuzumab plus chemotherapy improves survival in early-stage HER2-positive breast cancer patients.

[No authors listed]

Oncology (Williston Park). 2005 Jun;19(7):851, 862. No abstract available.

PMID:
16053034
15.

Expanded use of Herceptin.

[No authors listed]

FDA Consum. 2007 Mar-Apr;41(2):4-5. No abstract available.

16.

A meta-analysis of randomized controlled trials comparing chemotherapy plus trastuzumab with chemotherapy alone in HER-2-positive advanced breast cancer.

Liao C, Yin F, Huang P, Cao Y, Gao F.

Breast J. 2011 Jan-Feb;17(1):109-11. doi: 10.1111/j.1524-4741.2010.01034.x. Epub 2010 Dec 6. Review. No abstract available.

PMID:
21129096
17.

Survival benefit in early stage breast cancer of Herceptin plus a chemotherapy regimen lacking adriamycin.

[No authors listed]

Cancer Biol Ther. 2006 Jan;5(1):6-7. No abstract available.

PMID:
16924762
18.

Herceptin raises its sights beyond advanced breast cancer.

McNeil C.

J Natl Cancer Inst. 1998 Jun 17;90(12):882-3. No abstract available.

PMID:
9637135
19.

Development of new targeted therapies for breast cancer.

Doyle DM, Miller KD.

Cancer Treat Res. 2008;141:119-34. Review. No abstract available.

PMID:
18274086
20.

Preoperative chemotherapy plus lapatinib or trastuzumab or both in HER2-positive operable breast cancer (CHERLOB Trial).

Guarneri V, Frassoldati A, Piacentini F, Jovic G, Giovannelli S, Oliva C, Conte P.

Clin Breast Cancer. 2008 Apr;8(2):192-4. doi: 10.3816/CBC.2008.n.022. No abstract available.

PMID:
18621618

Supplemental Content

Support Center